WO2025247355 - MACROCYCLIC EGFR DEGRADER COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/247355
Publication Date
04.12.2025
International Application No.
PCT/CN2025/098204
International Filing Date
29.05.2025
Title **
[English]
MACROCYCLIC EGFR DEGRADER COMPOUND AND USE THEREOF
[French]
COMPOSÉ DE DÉGRADATION DE L'EGFR MACROCYCLIQUE ET SON UTILISATION
[Chinese]
大环类EGFR降解剂化合物及其应用
Applicants **
SHANGHAI XIANXIANG MEDICAL TECHNOLOGY CO., LTD.
Inventors
ZHU, Dongxing
XUE, Jianbin
WANG, Tao
ZHU, Wei
YANG, Shuqun
LI, Zhengtao
TANG, Renhong
Priority Data
202410688893.7
30.05.2024
CN
202510057521.9
14.01.2025
CN
202510567928.6
30.04.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2622 | |
| EPO | Filing, Examination, Granting | 18663 | |
| Japan | Filing, Examination, Granting | 2461 | |
| South Korea | Filing, Examination, Granting | 2867 | |
| USA | Filing, Examination, Granting | 6190 |
Total:
32,803
Contact Us
Abstract[English]
The present application relates to a degrader compound targeting EGFR, and specifically provides a compound as represented by formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof. The compound has the substituents and structural features described in the present application. The present application further provides a pharmaceutical composition comprising the compound as represented by formula (I) or the stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutical use of the compound or the stereoisomer or pharmaceutically acceptable salt thereof.[French]
La présente invention concerne un composé de dégradation ciblant l'EGFR, et concerne plus précisément un composé tel que représenté par la formule (I) ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci. Le composé a les substituants et les caractéristiques structurales décrits dans la présente demande. La présente invention concerne en outre une composition pharmaceutique comprenant le composé tel que représenté par la formule (I) ou le stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, et une utilisation pharmaceutique du composé ou du stéréoisomère ou du sel pharmaceutiquement acceptable de celui-ci.[Chinese]
本公开内容涉及靶向EGFR的降解剂化合物，具体提供了式(I)的化合物或其立体异构体或其药学上可接受的盐，所述化合物具有本申请所述取代基和结构特征。本申请还描述了包含式(I)化合物或其立体异构体或其药学上可接受的盐的药物组合物，以及所述化合物或其立体异构体或其药学上可接受的盐在医药上的应用。